Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

PANVIPREP · Developing broad-spectrum antiviral drugs for pandemic preparedness

HORIZONStatus: SIGNED1 January 202431 December 2027EU funding €7,999,295Call HORIZON-HLTH-2023-DISEASE-03

Antiviral drugs will be key in the management of future virus outbreaks. For each virus family with epidemic/pandemic potential, stockpiles of potent drugs are needed that can be deployed when a new pathogen emerges. Such broader-acting drugs (targeting conserved viral functions) are needed as of “day one” of an outbreak, for treatment and prophylaxis (e.g., in HCW and frail patients). In combination with quarantine measures, such drugs will delay (global) spread, allowing time for vaccine-development. Since the 2003 SARS outbreak, PANVIPREP’s core partners have successfully collaborated in leading European antiviral drug research projects. This provides a solid scientific basis in combination with translational drug discovery expertise. The team includes virologists, biochemists, structural biologists, medicinal chemists and pharmacokinetics experts. Previously developed know-how and toolboxes will be a major asset to achieve immediate impact. PANVIPREP aims to greatly expand the antiviral portfolio and identify novel druggable targets of high-risk RNA viruses. Hits will be identified through (i) phenotypic antiviral screening of compound libraries (ii) structure-based drug design, (iii) in silico screening, supported by the latest machine-learning methods. We will deliver 25 to 50 high-quality, broad(er)-spectrum (pan-genus/pan-family) hit molecules/hit series. Two of these will be developed to the early lead stage, including proof of concept in animal infection models. Remaining hits will serve as chemical tool-compounds to explore mechanisms of action thereby identifying novel druggable targets in RNA virus replication. This in turn will accelerate target-based drug design efforts. The workflow will integrate best practices in antiviral drug discovery with a range of methodological innovations, including AI-based methods, thus renovating and accelerating the antiviral hit discovery pipeline future use and contributing to pandemic preparedness.

Consortium · 17 organisations

coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

NL · €1,204,305

thirdParty

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR

associatedPartner

EPITHELIX SARL

CH

participant

JIHOCESKA UNIVERZITA V CESKYCH BUDEJOVICICH

CZ · €250,000

participant

VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE

CZ · €450,000

participant

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

ES · €458,083

participant

Zafiro Business Solutions Korlatolt Felelossegu Tarsasag

HU · €167,000

participant

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

DE · €550,102

associatedPartner

EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT

CH

associatedPartner

EIDGENOESSISCHES DEPARTEMENT DES INNERN

CH

thirdParty

CENTRUM VOOR INNOVATIE EN STIMULATIE VAN MEDICIJNONTWIKKELING LEUVEN VZW

BE

participant

UNIVERSITE D'AIX MARSEILLE

FR · €1,147,525

participant

UNIVERSITEIT UTRECHT

NL · €535,000

thirdParty

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR

participant

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €2,588,546

participant

UNIVERSITAET zu LUEBECK

DE · €250,000

participant

JANSSEN PHARMACEUTICA NV

BE · €398,735

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.